ASCENTAGE PHARMA
LIVE

Serial Number

79246610

Owner

Jiangsu Ascentage Pharma Inc.

Attorney

Kathryn E. Smith

Filing Date

Aug 10, 2018

Add to watchlist:

No watchlists yet
View on USPTO

ASCENTAGE PHARMA Trademark

Serial Number: 79246610 • Registration: 5876589

ASCENTAGE PHARMA is a trademark filed by Jiangsu Ascentage Pharma Inc. on August 10, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Jiangsu Ascentage Pharma Inc. (6 trademarks)

101 Room Of First Floor, Qb3 Buiding,

Entity Type: 99

ASCENTAGE PHARMA (SUZHOU) CO., LTD. (23 trademarks)

68 XINQING ROAD
SUZHOU 215000 , CN

Entity Type: 03

JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.

Room 101, F/1, Phase 1,

Entity Type: 03

Trademark Details

Filing Date

August 10, 2018

Registration Date

October 8, 2019

Published for Opposition

July 23, 2019

Goods & Services

Medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; drugs for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical or medical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicines for dental purposes; antibiotics; pharmaceutical preparations in the form of injection for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of tablet for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; active pharmaceutical ingredients in the nature of drug delivery agents in the form of powders, liquids, and capsules that provide controlled release of active ingredients for a wide variety of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; active pharmaceutical ingredients for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories; medicinal oils; transdermal patches for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; candy, medicated; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic substances adapted for medical use; mineral food supplements; nutritional supplements

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Apr 23, 2026 NREP
TEAS SECTION 71 RECEIVED
Apr 7, 2026 ES71
CHANGE OF OWNER RECEIVED FROM IB
Nov 7, 2025 CHLD
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 21, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 21, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 21, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 21, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 21, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 21, 2025 COAR
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Oct 8, 2024 REM3
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Apr 1, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 1, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 1, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 1, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 1, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 1, 2024 COAR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 27, 2023 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Dec 25, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 13, 2020 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Feb 3, 2020 XXSS
GENERIC MADRID TRANSACTION CREATED
Feb 3, 2020 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 8, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 8, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 23, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jul 23, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 3, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 14, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 13, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 12, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 12, 2019 TROA
REFUSAL PROCESSED BY IB
Jan 11, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 21, 2018 RFCS
REFUSAL PROCESSED BY MPU
Dec 20, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 11, 2018 RFCR
NON-FINAL ACTION WRITTEN
Dec 10, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Dec 4, 2018 MAFR
ASSIGNED TO EXAMINER
Nov 30, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 30, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 29, 2018 REPR